| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Richard A. Heyman is Director at ORIC and has filed Form 4s across 3 companies. Richard A. Heyman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.3M at current prices.
Historically, Richard A. Heyman's trades have earned a strong insider score of 73/100 across 42 rated trades. Over a 12-month horizon, 77.1% of those trades were profitable, with an average 12-month return of +35.1%.
The biggest single holding is ORIC (~$2.3M) as Director. The ORIC filings lean toward selling, a net 38,028 shares.
Richard A. Heyman has 54 Form 4 filings on record from August 2015 to October 2026, across 4 companies: Director at ORIC Pharmaceuticals (ORIC), 2020–2026; Director at Enliven Therapeutics (ELVN), 2023–2026; Director at PMV Pharmaceuticals (PMVP), 2020–2025, and 1 more.
The 95 reported transactions were 64 open-market sales, 20 option or other derivative awards, 7 option exercises and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 32 sales worth about $1.8M.
The largest open-market sale was 13,920 shares of ELVN at an average $25.02 on January 9, 2026, about $348K.
All 23 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 6,700 | $12.91 | $86,524.47 | -2.7% | - | - | |
| Jul 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 13,100 | $12.02 | $157,462.00 | -6.0% | +12.6% | - | |
| Jul 6, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell10b5-1 | 300 | $12.00 | $3,600.00 | -0.1% | +14.5% | - | |
| Feb 17, 2026 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,230 | $26.18 | $32,196.36 | -5.2% | +51.7% | - | |
| Jan 20, 2026 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,230 | $26.75 | $32,901.52 | -4.9% | +71.6% | - | |
| Jan 16, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell10b5-1 | 6,700 | $12.00 | $80,430.82 | -3.0% | -15.6% | - | |
| Jan 9, 2026 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 13,920 | $25.02 | $348,280.95 | -35.7% | +75.3% | - | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,570 | $30.00 | $47,104.03 | -5.5% | -24.2% | -26.2% | |
| Oct 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 1,270 | $27.67 | $35,143.31 | -1.0% | -20.7% | -21.9% | |
| Oct 4, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell10b5-1 | 2,825 | $27.51 | $77,703.60 | -2.2% | -13.2% | -28.8% |